2017-12-05 from cbc.ca

The World Health Organization said on Monday it hoped to conduct a full review by the end of the year of a dengue vaccine that was suspended last week in the Philippines.  

The Philippines also ordered an investigation on Monday. On Friday, the department of health halted its dengue immunization program after the manufacturer, French drug company Sanofi Pasteur, announced the vaccine must be strictly limited due to evidence it can worsen dengue in people not previously exposed to the infection. 

More than 730,000 children in the Philippines have received the vaccine, commonly known as Dengvaxia.

The WHO has recommended that the vaccine only be used in people who have had a prior dengue infection.

The government of Brazil, where dengue is common, confirmed it already had recommended restricted use of the vaccine but had not suspended it entirely.

Amid mounting public concern, Sanofi explained its "new findings" at a news conference in Manila on Monday but did not say why action was not taken after a WHO report in mid-2016 that identified the risk the company was now flagging.

Read more here